Liver transplant drug showdown: which lowers pressure better?
NCT ID NCT07304466
First seen Jan 10, 2026 · Last updated Jun 15, 2026 · Updated 30 times
Summary
This study tests two drugs, terlipressin and somatostatin, to see which one better lowers high blood pressure in the liver's main vein during a living-donor liver transplant. High pressure can cause dangerous bleeding, so finding the best drug may improve safety. About 50 adults with severe liver disease and high portal pressure will receive one of the drugs during surgery and be monitored for 7 days after.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PORTAL HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istanbul Medipol University Medipol Mega Hospital
RECRUITINGIstanbul, Bagcilar, 34218, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.